224 results on '"Kruse, Niels"'
Search Results
2. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression
3. TREM2 expression in the brain and biological fluids in prion diseases
4. Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
5. Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases
6. Quantification of Alpha-Synuclein in Biological Fluids by Electrochemiluminescence-Based Detection
7. Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease
8. Molecular Alterations in the Cerebellum of Sporadic Creutzfeldt–Jakob Disease Subtypes with DJ-1 as a Key Regulator of Oxidative Stress
9. Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study
10. Neurofilament light chains in serum as biomarkers of axonal damage in early MS lesions: a histological–serological correlative study
11. Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies
12. Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD
13. Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline
14. Extracellular vesicle sorting of α-Synuclein is regulated by sumoylation
15. Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases
16. Baseline Cerebrospinal Fluid 0̆3b1-Synuclein in Parkinson's Disease Is Associated with Disease Progression and Cognitive Decline
17. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies
18. Natalizumab analogon therapy is effective in a B cell-dependent multiple sclerosis model
19. Systematic Assessment of 10 Biomarker Candidates Focusing on α‐Synuclein‐Related Disorders
20. Anesthesia triggers drug delivery to experimental glioma in mice by hijacking caveolar transport
21. Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates
22. Differential expression of BDNF mRNA splice variants in mouse brain and immune cells
23. A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation
24. Recommendations to standardize preanalytical confounding factors in Alzheimerʼs and Parkinsonʼs disease cerebrospinal fluid biomarkers: an update
25. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates
26. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis
27. HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype
28. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis
29. Evaluation of diagnostic relevance of mRNA levels in peripheral blood: predictive value for mortality in hemodialysis patients
30. Effects of Oncostatin M on Human Cerebral Endothelial Cells and Expression in Inflammatory Brain Lesions
31. Genetic polymorphism of the tumor necrosis factor (TNF)-α promoter region in families with localized early-onset periodontitis
32. Autoantibodies to BP180 Associated with Bullous Pemphigoid Release Interleukin-6 and Interleukin-8 from Cultured Human Keratinocytes
33. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression
34. Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study
35. Genomic NGFB variation and multiple sclerosis in a case control study
36. Genetic variation at position –1082 of the interleukin 10 (IL10) promotor and the outcome of multiple sclerosis
37. O2‐09‐04: HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF α‐SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH
38. Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis
39. [P4-151]: ALPHA-SYNUCLEIN BIOMARKER ANALYSIS: ANALYTICAL PERFORMANCE AND INTER-LABORATORY PRECISION USING A NEW COLORIMETRIC ELISA
40. Validation of electrochemiluminescence assays for highly sensitive and reproducible quantification of α-synuclein in cerebrospinal fluid
41. Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease
42. Molecular Alterations in the Cerebellum of Sporadic Creutzfeldt–Jakob Disease Subtypes with DJ-1 as a Key Regulator of Oxidative Stress
43. Evaluation of α‐synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases
44. Antibody‐based methods for the measurement of α‐synuclein concentration in human cerebrospinal fluid – method comparison and round robin study.
45. Characterizing mild cognitive impairment in incident Parkinson disease:The ICICLE-PD Study
46. A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid
47. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies
48. Quantified CSF antibody reactivity against myelin in multiple sclerosis
49. Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human α-Synuclein in cerebrospinal fluid
50. HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF α-SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.